

(FILE 'HOME' ENTERED AT 11:42:14 ON 29 SEP 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 11:42:57 ON 29 SEP 2006  
SEA (DOSE(W)DENSE) AND CHEMOTHERAPY  
-----

92 FILE ADISCTI  
3 FILE ADISINSIGHT  
8 FILE ADISNEWS  
140 FILE BIOSIS  
24 FILE BIOTECHNO  
117 FILE CAPLUS  
6 FILE CONFSCI  
68 FILE DDFU  
84 FILE DRUGU  
6 FILE EMBAL  
182 FILE EMBASE  
100 FILE ESBIODASE  
1 FILE HEALSAFE  
2 FILE IFIPAT  
4 FILE JICST-EPLUS  
1 FILE LIFESCI  
193 FILE MEDLINE  
90 FILE PASCAL  
1 FILE PHAR  
1 FILE PHARMAML  
18 FILE PROMT  
223 FILE SCISEARCH  
310 FILE TOXCENTER  
4 FILE USPATFULL  
1 FILE WPIDS  
1 FILE WPINDEX

L1 QUE (DOSE(W) DENSE) AND CHEMOTHERAPY  
-----

FILE 'MEDLINE, SCISEARCH' ENTERED AT 11:44:52 ON 29 SEP 2006

L2 416 S (DOSE(W)DENSE) AND CHEMOTHERAPY  
L3 291 S L2 AND (BREAST(W)CANCER)  
L4 282 DUP REM L2 (134 DUPLICATES REMOVED)  
L5 77 S L4 NOT PY>2002  
L6 59 S L4 NOT PY>2001  
L7 10 S L6 AND DOXORUBICIN AND (PACLITAXEL OR TAXANE) AND CYCLOPHOSP  
L8 0 S L7 AND (WELL-TOLERATED)  
L9 0 S L7 AND (WELL(W)TOLERATED)

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 11:42:57 ON 29 SEP 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> s (dose(w)dense) and chemotherapy

```
92  FILE ADISCTI
3   FILE ADISINSIGHT
8   FILE ADISNEWS
140 FILE BIOSIS
24  FILE BIOTECHNO
13  FILES SEARCHED...
117 FILE CAPLUS
6   FILE CONFSCI
68  FILE DDFU
22  FILES SEARCHED...
84  FILE DRUGU
6   FILE EMBAL
182 FILE EMBASE
100 FILE ESBIODBASE
32  FILES SEARCHED...
1   FILE HEALSAFE
2   FILE IFIPAT
4   FILE JICST-EPLUS
1   FILE LIFESCI
193 FILE MEDLINE
90  FILE PASCAL
1   FILE PHAR
1   FILE PHARMAML
51  FILES SEARCHED...
18  FILE PROMT
223 FILE SCISEARCH
310 FILE TOXCENTER
4   FILE USPATFULL
65  FILES SEARCHED...
1   FILE WPIDS
1   FILE WPINDEX
```

26 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L1 QUE (DOSE(W) DENSE) AND CHEMOTHERAPY

=> fiel medline scisearch

FIEL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> file medline scisearch

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.83	2.04

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:44:52 ON 29 SEP 2006

FILE 'SCISEARCH' ENTERED AT 11:44:52 ON 29 SEP 2006

Copyright (c) 2006 The Thomson Corporation

=> s (dose(w)dense) and chemotherapy

L2 416 (DOSE(W) DENSE) AND CHEMOTHERAPY

=> s l2 and (breast(w)cancer)

L3 291 L2 AND (BREAST(W) CANCER)

=> dup rem l2

PROCESSING COMPLETED FOR L2

L4 282 DUP REM L2 (134 DUPLICATES REMOVED)

=> s l4 not py>2002

L5 77 L4 NOT PY>2002

=> d l5 1-10 ti

L5 ANSWER 1 OF 77 MEDLINE on STN

TI Dosage parameters in chemotherapy of breast cancer.

L5 ANSWER 2 OF 77 MEDLINE on STN

TI Weekly administration of paclitaxel: theoretical and clinical basis.

L5 ANSWER 3 OF 77 MEDLINE on STN

TI Role of weekly paclitaxel in the treatment of advanced ovarian cancer.

L5 ANSWER 4 OF 77 MEDLINE on STN

TI Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.

L5 ANSWER 5 OF 77 MEDLINE on STN

TI Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.

L5 ANSWER 6 OF 77 MEDLINE on STN

TI Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.

L5 ANSWER 7 OF 77 MEDLINE on STN

TI A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.

L5 ANSWER 8 OF 77 MEDLINE on STN

TI Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.

L5 ANSWER 9 OF 77 MEDLINE on STN

TI A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.

L5 ANSWER 10 OF 77 MEDLINE on STN

TI Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.

=> s 14 not py>2001  
L6 59 L4 NOT PY>2001

=> d 16 1-59 ti

- L6 ANSWER 1 OF 59 MEDLINE on STN  
TI Dosage parameters in chemotherapy of breast cancer.
- L6 ANSWER 2 OF 59 MEDLINE on STN  
TI Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
- L6 ANSWER 3 OF 59 MEDLINE on STN  
TI [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].  
Praoperative Chemotherapie operabler primärer Mammakarzinome mit einer dosisdichten Kombination von Adriamycin und Docetaxel (ADoc) - Die Erfahrungen der GEPARDO-GABG-Studiengruppe -.
- L6 ANSWER 4 OF 59 MEDLINE on STN  
TI Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
- L6 ANSWER 5 OF 59 MEDLINE on STN  
TI Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
- L6 ANSWER 6 OF 59 MEDLINE on STN  
TI Dose-dense and sequential strategies in adjuvant breast cancer therapy.
- L6 ANSWER 7 OF 59 MEDLINE on STN  
TI Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
- L6 ANSWER 8 OF 59 MEDLINE on STN  
TI Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
- L6 ANSWER 9 OF 59 MEDLINE on STN  
TI Theoretical concepts and the emerging role of taxanes in adjuvant therapy.
- L6 ANSWER 10 OF 59 MEDLINE on STN  
TI Whither high-dose chemotherapy in breast cancer?.
- L6 ANSWER 11 OF 59 MEDLINE on STN  
TI Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
- L6 ANSWER 12 OF 59 MEDLINE on STN  
TI Recent developments in weekly paclitaxel therapy in lung cancer.
- L6 ANSWER 13 OF 59 MEDLINE on STN  
TI Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.

L6 ANSWER 14 OF 59 MEDLINE on STN  
 TI A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

L6 ANSWER 15 OF 59 MEDLINE on STN  
 TI UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.

L6 ANSWER 16 OF 59 MEDLINE on STN  
 TI Update on adjuvant chemotherapy for early breast cancer.

L6 ANSWER 17 OF 59 MEDLINE on STN  
 TI Weekly schedule of vinorelbine in pretreated breast cancer patients.

L6 ANSWER 18 OF 59 MEDLINE on STN  
 TI Current opinion in germ cell cancer 2000.

L6 ANSWER 19 OF 59 MEDLINE on STN  
 TI An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.

L6 ANSWER 20 OF 59 MEDLINE on STN  
 TI Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.

L6 ANSWER 21 OF 59 MEDLINE on STN  
 TI Dose-dense chemotherapy for breast cancer: the story so far.

L6 ANSWER 22 OF 59 MEDLINE on STN  
 TI Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).

L6 ANSWER 23 OF 59 MEDLINE on STN  
 TI Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms.

L6 ANSWER 24 OF 59 MEDLINE on STN  
 TI 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

L6 ANSWER 25 OF 59 MEDLINE on STN  
 TI Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.

L6 ANSWER 26 OF 59 MEDLINE on STN  
 TI Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.

L6 ANSWER 27 OF 59 MEDLINE on STN  
 TI Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

L6 ANSWER 28 OF 59 MEDLINE on STN  
 TI UFT/calcium folinate plus weekly paclitaxel for solid tumors.

L6 ANSWER 29 OF 59 MEDLINE on STN  
 TI Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy.

L6 ANSWER 30 OF 59 MEDLINE on STN  
 TI Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.

L6 ANSWER 31 OF 59 MEDLINE on STN  
 TI Recently initiated studies: neoadjuvant treatments in the next century.

L6 ANSWER 32 OF 59 MEDLINE on STN  
 TI Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.

L6 ANSWER 33 OF 59 MEDLINE on STN  
 TI Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.

L6 ANSWER 34 OF 59 MEDLINE on STN  
 TI Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.

L6 ANSWER 35 OF 59 MEDLINE on STN  
 TI Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and  $\geq 10$  positive axillary lymph nodes. A feasibility study.

L6 ANSWER 36 OF 59 MEDLINE on STN  
 TI Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

L6 ANSWER 37 OF 59 MEDLINE on STN  
 TI One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index.

L6 ANSWER 38 OF 59 MEDLINE on STN  
 TI Dose-dense paclitaxel-containing adjuvant therapy for breast cancer.

L6 ANSWER 39 OF 59 MEDLINE on STN  
 TI Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.

L6 ANSWER 40 OF 59 MEDLINE on STN  
 TI Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.

L6 ANSWER 41 OF 59 MEDLINE on STN  
 TI Evolving concepts in the systemic drug therapy of breast cancer.

L6 ANSWER 42 OF 59 MEDLINE on STN  
 TI Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide.

L6 ANSWER 43 OF 59 MEDLINE on STN  
 TI New approaches to adjuvant chemotherapy for breast cancer.

L6 ANSWER 44 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 TI Dose-dense weekly (8 weeks) vs. sequential (24 weeks) neoadjuvant chemotherapy with adriamycin/cyclophosphamide and

docetaxel in operable breast cancer (T2-3, N0-2, M0)-interim analysis of the Geparduo trial-.

- L6 ANSWER 45 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel (taxol (R)) and CMF (E-T-CMF) vs epirubicin and CMF (E-CMF) in high-risk patients with breast cancer (BC).
- L6 ANSWER 46 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Dose-intense, dose-dense (F)AC+G adjuvant chemotherapy has excellent event-free survival in highrisk patients with 4-9 involved axillary nodes.
- L6 ANSWER 47 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors
- L6 ANSWER 48 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Dose-dense chemotherapy with paclitaxel and carboplatin in stage III-IV ovarian cancer: Pathologic response and outcome of pilot study.
- L6 ANSWER 49 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Dose-dense mitoxantrone and doxetaxel as first line chemotherapy in patients with metastatic breast cancer: A pilot study.
- L6 ANSWER 50 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first line chemotherapy, in advanced breast cancer.
- L6 ANSWER 51 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Tandem high-dose chemotherapy (HDC) versus dose-dense conventional chemotherapy in high-risk breast cancer (HRBC): Regular interim analysis of a randomized trial from the WSG.
- L6 ANSWER 52 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Phase III study comparing standard vs dose-dense epirubicin- containing chemotherapy in early breast cancer: Predictive role of HER2.
- L6 ANSWER 53 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Dose-dense chemotherapy for breast cancer: the story so far
- L6 ANSWER 54 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
TI Disease oriented treatment of metastatic colorectal cancer (CRC) with dose-dense 5-FU/Folinic acid (FU/FA) combination chemotherapy
- L6 ANSWER 55 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols

L6 ANSWER 56 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Tandem high-dose chemotherapy (HDC) versus dose-dense conventional chemotherapy for patients with high-risk breast cancer (HRBC) - interim results from a multicenter phase III trial

L6 ANSWER 57 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study

L6 ANSWER 58 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

L6 ANSWER 59 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in patients with operable breast cancer and  $\geq 10$  positive axillary nodes

=> s l6 and doxorubicin and (paclitaxel or taxane) and cyclophosphamide

L7 10 L6 AND DOXORUBICIN AND (PACLITAXEL OR TAXANE) AND CYCLOPHOSPHAMIDE

=> d l7 1-10

L7 ANSWER 1 OF 10 MEDLINE on STN

AN 2002048208 MEDLINE

DN PubMed ID: 11751485

TI Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

AU Fornier M N; Seidman A D; Theodoulou M; Moynahan M E; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas K S; Norton L; Hudis C

CS Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2001 Dec) Vol. 7, No. 12, pp. 3934-41. Journal code: 9502500. ISSN: 1078-0432.

CY United States

DT (CLINICAL TRIAL)  
(CLINICAL TRIAL, PHASE II)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals

EM 200203

ED Entered STN: 25 Jan 2002  
Last Updated on STN: 3 Apr 2002  
Entered Medline: 27 Mar 2002

L7 ANSWER 2 OF 10 MEDLINE on STN



AN 2001328759 MEDLINE  
 DN PubMed ID: 11396366  
 TI Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.  
 AU Trudeau M E  
 CS Division of Medical Oncology/Hematology, Toronto Sunnybrook, Regional Cancer Centre, Toronto, Canada.  
 SO Oncology (Williston Park, N.Y.), (2001 May) Vol. 15, No. 5 Suppl 7, pp. 7-13. Ref: 29  
 Journal code: 8712059. ISSN: 0890-9091.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 200110  
 ED Entered STN: 29 Oct 2001  
 Last Updated on STN: 11 Dec 2002  
 Entered Medline: 25 Oct 2001

L7 ANSWER 3 OF 10 MEDLINE on STN  
 AN 2000419046 MEDLINE  
 DN PubMed ID: 10950143  
 TI An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.  
 AU Gilewski T; Seidman A; Norton L; Hudis C  
 CS Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.  
 SO Cancer chemotherapy and pharmacology, (2000) Vol. 46 Suppl, pp. S23-6. Ref: 22  
 Journal code: 7806519. ISSN: 0344-5704.  
 CY GERMANY: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 200009  
 ED Entered STN: 15 Sep 2000  
 Last Updated on STN: 15 Sep 2000  
 Entered Medline: 6 Sep 2000

L7 ANSWER 4 OF 10 MEDLINE on STN  
 AN 1999385404 MEDLINE  
 DN PubMed ID: 10458222  
 TI Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.  
 AU Hudis C; Seidman A; Baselga J; Raptis G; Lebwohl D; Gilewski T; Moynahan M; Sklarin N; Fennelly D; Crown J P; Surbone A; Uhlenhopp M; Riedel E; Yao T J; Norton L  
 CS Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.. hudisc@mskcc.org  
 NC CM-07311 (NCI)  
 P50-CA68425 (NCI)  
 SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (1999 Jan) Vol. 17, No. 1, pp. 93-100.  
 Journal code: 8309333. ISSN: 0732-183X.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199909

ED Entered STN: 21 Sep 1999  
 Last Updated on STN: 21 Sep 1999  
 Entered Medline: 3 Sep 1999

L7 ANSWER 5 OF 10 MEDLINE on STN  
 AN 1999368023 MEDLINE  
 DN PubMed ID: 10439168  
 TI Adjuvant sequential dose-dense doxorubicin,  
 paclitaxel, and cyclophosphamide (ATC) for high-risk  
 breast cancer is feasible in the community setting.  
 AU Burtress B; Windsor S; Holston B; DiStasio S; Staugaard-Hahn C; Abrantes  
 J; Kneuper-Hall R; Farber L; Orell J; Bober-Sorcinelli K; Haffty B G;  
 Reiss M  
 CS Department of Internal Medicine, Yale University School of Medicine, New  
 Haven, Connecticut 06520-8032, USA.  
 SO The cancer journal from Scientific American, (1999 Jul-Aug) Vol. 5, No. 4,  
 pp. 224-9.  
 Journal code: 9513568. ISSN: 1081-4442.  
 CY United States  
 DT (CLINICAL TRIAL)  
 (CLINICAL TRIAL, PHASE II)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199910  
 ED Entered STN: 26 Oct 1999  
 Last Updated on STN: 26 Oct 1999  
 Entered Medline: 8 Oct 1999

L7 ANSWER 6 OF 10 MEDLINE on STN  
 AN 1998177240 MEDLINE  
 DN PubMed ID: 9516597  
 TI Dose-dense paclitaxel-containing adjuvant  
 therapy for breast cancer.  
 AU Hudis C A  
 CS Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York,  
 NY, USA.  
 SO Oncology (Williston Park, N.Y.), (1998 Jan) Vol. 12, No. 1 Suppl 1, pp.  
 16-8.  
 Journal code: 8712059. ISSN: 0890-9091.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 199804  
 ED Entered STN: 30 Apr 1998  
 Last Updated on STN: 30 Apr 1998  
 Entered Medline: 21 Apr 1998

L7 ANSWER 7 OF 10 MEDLINE on STN  
 AN 1998031119 MEDLINE  
 DN PubMed ID: 9364536  
 TI Docetaxel as neoadjuvant chemotherapy in patients with stage III  
 breast cancer.  
 AU Gradishar W J  
 CS Breast Medical Oncology Multidisciplinary Program, Northwestern  
 University, Chicago, Illinois, USA.  
 SO Oncology (Williston Park, N.Y.), (1997 Aug) Vol. 11, No. 8 Suppl 8, pp.  
 15-8.  
 Journal code: 8712059. ISSN: 0890-9091.  
 CY United States  
 DT (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)

LA English  
FS Priority Journals  
EM 199712  
ED Entered STN: 9 Jan 1998  
Last Updated on STN: 9 Jan 1998  
Entered Medline: 18 Dec 1997

L7 ANSWER 8 OF 10 MEDLINE on STN  
AN 97289900 MEDLINE  
DN PubMed ID: 9144685  
TI Sequential dose-dense adjuvant therapy with  
doxorubicin, paclitaxel, and cyclophosphamide.  
AU Hudis C  
CS Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center,  
Cornell University Medical College New York, New York 10021, USA.  
SO Oncology (Williston Park, N.Y.), (1997 Apr) Vol. 11, No. 4 Suppl 3, pp.  
15-8. Ref: 25  
Journal code: 8712059. ISSN: 0890-9091.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA English  
FS Priority Journals  
EM 199707  
ED Entered STN: 24 Jul 1997  
Last Updated on STN: 24 Jul 1997  
Entered Medline: 14 Jul 1997

L7 ANSWER 9 OF 10 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 2001:70832 SCISEARCH  
GA The Genuine Article (R) Number: 390NG  
TI Paclitaxel-based chemotherapy for patients with  
refractory or relapsed nonseminomatous germ cell tumors  
AU Amato R J (Reprint); Prow D M  
CS Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515  
Holcombe Blvd, Box 013, Houston, TX 77030 USA (Reprint); Univ Texas, MD  
Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA  
CYA USA  
SO UROLOGIC ONCOLOGY, (JUL-AUG 2000) Vol. 5, No. 4, pp. 134-138.  
ISSN: 1078-1439.  
PB ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA.  
DT General Review; Journal  
LA English  
REC Reference Count: 21  
ED Entered STN: 26 Jan 2001  
Last Updated on STN: 26 Jan 2001  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L7 ANSWER 10 OF 10 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 2000:413511 SCISEARCH  
GA The Genuine Article (R) Number: 319QB  
TI Dose-dense chemotherapy for breast cancer:  
the story so far  
AU Hudis C (Reprint)  
CS Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, 1275 York Ave, New  
York, NY 10021 USA (Reprint); Mem Sloan Kettering Canc Ctr, Breast Canc  
Med Serv, New York, NY 10021 USA  
CYA USA

SO BRITISH JOURNAL OF CANCER, (JUN 2000) Vol. 82, No. 12, pp. 1897-1899.  
ISSN: 0007-0920.  
PB CHURCHILL LIVINGSTONE, JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE,  
1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND.  
DT Editorial; Journal  
LA English  
REC Reference Count: 17  
ED Entered STN: 2000  
Last Updated on STN: 2000

=> s 17 and (well-tolerated)  
L8 0 L7 AND (WELL-TOLERATED)

=> s 17 and (well(w)tolerated)  
L9 0 L7 AND (WELL(W) TOLERATED)

=> d his